Status:
COMPLETED
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Must have diagnosis of relapsed or refractory multiple.
- bone marrow function \[ANC (absolute neutrophil count) greater than 1000/mm3\]; platelet count greater than or equal to 75,000/mm3.
- renal function (calculated creatinine clearance \>50 mL.min, albumin less than or equal to 500 mg).
- Exclusion criteria:
- Failed more than 3 prior lines of therapy including stem cell transplant.
- Females who are pregnant or nursing.
- Unstable blood pressure.
- Significant heart conditions or history of thrombosis.
- Any unstable, pre-existing major medical condition or history of other cancers.
- Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00256880
Start Date
January 1 2005
End Date
December 1 2005
Last Update
January 18 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
2
GSK Investigational Site
Boston, Massachusetts, United States, 02115
3
GSK Investigational Site
Durham, North Carolina, United States, 27710
4
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104